Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coral LaboratoriesBOM:524506 72 PB Ratio is 0.99 as of Aug. 11, 2026, which is 8% above its 10-year median of 0.92. GuruFocus rates BOM:524506 with a GF Score™ of 72/100 and a GF Value™ of ₹483.47 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 920 Drug Manufacturers companies, Coral Laboratories ranks better than 77.17% on this metric.
Coral Laboratories Ltd stock PB Ratio (=0.99) is close to 1-year high of 1.07.
The historical rank and industry rank for Coral Laboratories's PB Ratio or its related term are showing as below:
BOM:524506'
s PB Ratio Range Over the Past 10 Years
Min: 0.31 Med: 0.92 Max: 3.63
Current: 0.99
During the past 13 years, Coral Laboratories's highest PB Ratio was 3.63. The lowest was 0.31. And the median was 0.92.
BOM:524506's PB Ratio is ranked better than 77.17% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.97
vs BOM:524506: 0.99
During the past 12 months, Coral Laboratories's average Book Value Per Share Growth Rate was 3.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 10.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 9.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 9.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Coral Laboratories was 29.20% per year. The lowest was 2.00% per year. And the median was 13.65% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Coral Laboratories PB Ratio Related Terms
Coral Laboratories PB Ratio Historical Data
* Premium members only.
The historical data trend for Coral Laboratories's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Coral Laboratories's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coral Laboratories PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Coral Laboratories's PB Ratio distribution charts can be found below:
* The bar in red indicates where Coral Laboratories's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Coral Laboratories (BOM:524506) has a PB Ratio of 0.99 as of Aug. 11, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Coral Laboratories and its competitors. This is near median its historical median of 0.92. Over the past decade, Coral Laboratories' PB Ratio has ranged from 0.31 to 3.63. According to the industry distribution chart, Coral Laboratories ranks #210 out of 920 companies in the Drug Manufacturers industry, placing it in the top 22.8%.
Is Coral Laboratories' PB Ratio too high?
Coral Laboratories' current PB Ratio of 0.99 is near median its 10-year median of 0.92. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 3.63. The Drug Manufacturers industry median PB Ratio is 1.97. Coral Laboratories' value of 0.99 is 49.7% below this industry median. Based on the distribution chart, Coral Laboratories ranks #210 out of 920 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Coral Laboratories has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coral Laboratories' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Coral Laboratories ranks #210 out of 920 companies for PB Ratio. This places Coral Laboratories in the top 23% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.97. Coral Laboratories' value of 0.99 is 49.7% below this benchmark. Historically, Coral Laboratories' own PB Ratio has ranged from 0.31 to 3.63 over the past decade. While the company's 10-year median is 0.92 vs. the industry median of 1.97, Coral Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.97, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coral Laboratories's current PB Ratio of 0.99 is 49.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Coral Laboratories and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coral Laboratories's current PB Ratio is 0.99, which is near median its own 10-year median of 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coral Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Coral Laboratories (BOM:524506) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹483.47, compared to a current price of ₹577.90 — trading 19.5% above its estimated fair value. The current PB Ratio is 0.99, which is near median its 10-year median of 0.92 and 49.7% below the Drug Manufacturers industry median of 1.97. Coral Laboratories' overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Coral Laboratories (BOM:524506), the current PB Ratio is 0.99 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coral Laboratories (BOM:524506) Overvalued in 2026?
Based on GuruFocus' analysis, Coral Laboratories stock appears to be overvalued.
The current stock price of ₹577.90 is trading 19.5% above its estimated GF Value™ of ₹483.47.
GuruFocus considers Coral Laboratories to be Modestly Overvalued.
Key valuation signals for BOM:524506:
PB Ratio: 0.99 (near median its 10-year median of 0.92)
GF Value™: ₹483.47 vs. price of ₹577.90 (19.5% above fair value)
Industry Position: 49.7% below the Drug Manufacturers median (#210 of 920)
No single metric tells the full story. See the BOM:524506 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coral Laboratories Ltd is engaged in the pharmaceutical business. The company is involved in the formulation of medicines. The company's dosage form includes tablets, capsules, liquid orals, b-lactam, dry syrup, meter dose inhalers, injectables, drops, sprays, special kits, and others. Its geographical segments include Ethiopia, India, and the Rest of the world.
72GF Score
Get the complete analysis for BOM:524506
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524506 has been successfully added to your 
